Entropy Technologies LP Grows Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY

Entropy Technologies LP increased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 1,461.9% in the 3rd quarter, HoldingsChannel reports. The firm owned 17,181 shares of the biopharmaceutical company’s stock after purchasing an additional 16,081 shares during the period. Alnylam Pharmaceuticals makes up 0.6% of Entropy Technologies LP’s investment portfolio, making the stock its 29th biggest position. Entropy Technologies LP’s holdings in Alnylam Pharmaceuticals were worth $7,835,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Kennedy Capital Management LLC raised its position in Alnylam Pharmaceuticals by 93.0% in the 3rd quarter. Kennedy Capital Management LLC now owns 3,220 shares of the biopharmaceutical company’s stock valued at $1,468,000 after purchasing an additional 1,552 shares in the last quarter. Certuity LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at about $213,000. Quadrature Capital Ltd grew its position in shares of Alnylam Pharmaceuticals by 2,492.5% during the third quarter. Quadrature Capital Ltd now owns 48,920 shares of the biopharmaceutical company’s stock worth $22,299,000 after buying an additional 47,033 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its stake in shares of Alnylam Pharmaceuticals by 698.8% during the third quarter. Arrowstreet Capital Limited Partnership now owns 1,355,609 shares of the biopharmaceutical company’s stock worth $618,158,000 after buying an additional 1,185,909 shares during the period. Finally, Employees Retirement System of Texas increased its stake in shares of Alnylam Pharmaceuticals by 3.4% during the third quarter. Employees Retirement System of Texas now owns 9,792 shares of the biopharmaceutical company’s stock worth $4,465,000 after buying an additional 318 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 1.0%

ALNY stock opened at $317.23 on Friday. The stock has a market cap of $42.07 billion, a P/E ratio of 185.51 and a beta of 0.36. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $495.55. The company’s 50 day moving average is $346.09 and its two-hundred day moving average is $410.94.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.43 by ($0.18). The company had revenue of $1.10 billion during the quarter, compared to analyst estimates of $1.16 billion. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The company’s quarterly revenue was up 84.9% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.65) EPS. Research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 6,799 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $327.65, for a total transaction of $2,227,692.35. Following the sale, the chief executive officer owned 98,628 shares in the company, valued at approximately $32,315,464.20. The trade was a 6.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Pushkal Garg sold 1,775 shares of the business’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $319.74, for a total value of $567,538.50. Following the completion of the sale, the executive vice president directly owned 23,406 shares of the company’s stock, valued at $7,483,834.44. The trade was a 7.05% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 53,923 shares of company stock valued at $18,072,087 over the last quarter. 1.50% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on ALNY. Leerink Partners decreased their price target on shares of Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating for the company in a research note on Monday, December 15th. Wall Street Zen downgraded shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 14th. Barclays initiated coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday, January 28th. They issued an “overweight” rating and a $527.00 price objective on the stock. Raymond James Financial reaffirmed an “outperform” rating and set a $472.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, January 12th. Finally, Bank of America reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Thursday, February 12th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $477.96.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.